New York, May 20, 2026, 11:07 EDT
MeiraGTx Holdings plc shares rose 48 cents, or about 5.3%, to $9.61 in late-morning Nasdaq trading on Wednesday, lifting the gene-therapy developer to a market value of about $781 million. The stock opened at $9.33 and traded as high as $9.71.
The move came a day after an SEC Form 4 showed President and CEO Alexandria Forbes sold 62,000 ordinary shares on May 19 at a weighted average price of $9.17. The filing said the sale was made under a Rule 10b5-1 plan, a pre-arranged insider trading plan, adopted on Nov. 18, 2025; Forbes retained 1,387,695 shares directly after the transaction.
Why it matters now: MeiraGTx is trying to shift investor attention from funding risk to late-stage assets. In its May 14 update, the company said it had received FDA Breakthrough Therapy Designation for AAV2-hAQP1, reported three-year data in radiation-induced xerostomia, agreed to reacquire bota-vec from Johnson & Johnson, and strengthened its balance sheet with a $100 million financing.
Forbes said the early-2026 moves had “materially strengthened” MeiraGTx and called the bota-vec reacquisition a “highly strategic” addition. The company said it was working on regulatory submissions for bota-vec in the U.S., EU, UK and Japan.
At a Bank of America healthcare conference, BofA Securities analyst Alec Stranahan framed the issue as the “single most important derisking event” the market may not have appreciated. Forbes replied that buying back RPGR from J&J was “the most derisking thing” the company had done, and said global approval was a “real focus.” Seeking Alpha
Breakthrough Therapy Designation is FDA status meant to speed development and review for serious conditions when early clinical evidence suggests a drug may offer a substantial improvement over available therapy. MeiraGTx said AAV2-hAQP1, its treatment candidate for radiation-induced xerostomia — severe dry mouth after radiation therapy — had shown durable patient-reported and salivary-flow improvements through 36 months in a 24-patient Phase 1 study.
The numbers still show a company before product sales. MeiraGTx reported $73.8 million in cash, cash equivalents and restricted cash at March 31, service revenue of $0.3 million for the quarter, and research and development expenses of $32.0 million. Its 10-Q said the company had not generated product revenue and posted a $46.3 million net loss for the quarter, wider than $40.0 million a year earlier.
But the downside case is plain. MeiraGTx said its cash, tax incentive receivable, $100 million public offering proceeds and remaining Hologen payments should fund operations into the second half of 2028, including debt repayments, but also warned those estimates could be wrong and that it could use cash faster than expected. That leaves clinical timing, regulatory talks and capital markets as real risks, not fine print.
The competitive backdrop is active. Lilly struck a MeiraGTx deal in November potentially worth more than $475 million for an experimental gene therapy for a rare inherited eye disease, while also moving deeper into eye-focused gene therapy through Adverum Biotechnologies. For MeiraGTx, that keeps the company tied to larger drugmakers even as it tries to own more of its late-stage pipeline again.
For now, MGTX is trading less like a mature drug stock and more like a clinical-execution story. The share move is real; the approvals, launches and cash assumptions still have to land.
